Sign up for the Talking Points newsletter, a recap of the most important business news, delivered fresh each afternoon, Monday through Friday.
---
Jounce Therapeutics Inc., a four-year-old cancer immunotherapy startup, could be one of the first Massachusetts biotechs to test the IPO waters in 2017.
In a Dec. 30 regulatory filing, the Cambridge company said it will seek to raise $75 million — a sum that’s subject to change — in an initial public offering. The filing did not specify a timetable for completing the planned IPO.
Jounce, launched by Boston venture capital firm Third Rock Ventures, is developing drugs to enable patients’ immune systems to attack tumors. The focus of its lead drug candidate is T cells commonly found in solid tumors.
Last July, Jounce received a $225 million upfront payment from Celgene Corp., a New Jersey biotech that has invested in multiple Massachusetts companies, in a collaboration deal potentially worth up to $2.3 billion.
Robert Weisman can be reached at robert.weisman@globe.com. Follow him on Twitter @GlobeRobW.